Another study including a patient cohort of 41 prostate cancers previously reported CCL2 tissue expression in ~50% of cases, with patient outcome significantly worse with lower survival time in patients with CCL2 overexpressing tumours [28]. The gene discussed is CCL2; the disease is Familial prostate cancer.